Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.04 USD
Change Today -0.285 / -2.76%
Volume 1.1M
INO On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/14 - $14.20
52 Week Low
02/24/15 - $6.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, influenza, and Ebola. Inovio Pharmaceuticals, Inc. has collaborative development agreement with GeneOne Life Sciences to co-develop an Ebola vaccine through phase I clinical trials. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

106 Employees
Last Reported Date: 03/16/15
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $964.7K
Chief Financial Officer
Total Annual Compensation: $475.4K
Chief Operating Officer
Total Annual Compensation: $486.8K
Chief Medical Officer
Total Annual Compensation: $491.1K
Compensation as of Fiscal Year 2014.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc.'s HPV Immunotherapy Activates Robust in Vivo T Cell Responses in Head & Neck Cancer Patients

Inovio Pharmaceuticals, Inc. announced preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus types 16 and 18. INO-3112, an active immunotherapy that targets HPV 16 and 18 and simultaneously expresses IL-12, is designed to activate in vivo immune responses to antigens from high risk HPV types and eliminate precancerous and cancerous cells displaying these antigens. The data, which are T cell measurements from the first four treated patients of this phase I/IIa study, are being presented at the World Vaccine Congress 2015. These positive results represent the first study and first report of T cell immune responses generated in cancer patients after treatment with an Inovio DNA immunotherapy. The magnitude and characteristics of these interim immune response data mirror immune responses previously observed in human studies of VGX-3100 for HPV-associated cervical dysplasia; in a placebo-controlled phase II study, strong T cell immune responses were positively correlated with achievement of primary and secondary efficacy endpoints. This open label study of HPV-caused head and neck cancer is intended to assess the safety, tolerability, and immunogenicity of INO-3112 in up to twenty adults with HPV-positive head and neck squamous cell carcinoma. The study includes patients who are being treated with INO-3112 before and after resection of their tumor as well as patients being treated with INO-3112 after completion of chemotherapy and radiation therapy.

Inovio Pharmaceuticals Appoints Scott M. White, M.D as Vice President, Clinical Development -- Infectious Diseases

Inovio Pharmaceuticals, Inc. announced the appointment of Scott M. White, M.D. as Vice President, Clinical Development - Infectious Diseases. Dr. White will be responsible for advancing Inovio's infectious disease portfolio of DNA immunotherapies and vaccines through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer. Dr. White joins Inovio from GlaxoSmithKline where he spent more than a decade in positions of increasing responsibility leading global infectious disease clinical development programs. His most recent position was Senior Director and Project Physician Leader for skin-related infections.

Inovio Pharmaceuticals, Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Inovio Pharmaceuticals, Inc. reported consolidated financial results for the fourth quarter and year ended December 31, 2014. Total revenue was $2.5 million and $1.7 million for the quarter ended December 31, 2014, as compared to $1.1 million for the same period in 2013. The net loss attributable to common stockholders was $7.4 million, or $0.12 per share compared to net loss attributable to common stockholders of $15.5 million or $0.30 per share a year ago. For the year, the company reported total revenue was $10.5 million for the year ended December 31, 2014, as compared with $13.5 million for the same period in 2013. Loss from operations was $39.496 million against $19.544 million a year ago. The net loss attributable to common stockholders was $36.1 million, or $0.61 per share against $66.0 million, or $1.43 per share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $10.04 USD -0.285

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $19.47 USD -0.01
Dynavax Technologies Corp $23.58 USD -0.58
Genocea Biosciences Inc $12.89 USD +0.10
GenVec Inc $2.87 USD -0.03
Vical Inc $0.94 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.2x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at